Institut Bordet - Retour à la page d'accueil

Ahmad Hussein Awada

Department : Medical oncology, Clinical Trials Conduct Unit (CTCU) , Medicine department
 
ahmad.awada [at] bordet.be

Publications

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

Authors : Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, OShaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J
Year : 2019
Journal : Ann Oncol

Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results.

Authors : Catala G, Mebis J, Jerusalem G, Verhoeven D, Awada A, Bols A, Somers L, Van Den Broeck A, Duhoux FP, Machiels JP
Year : 2019
Journal : Acta Clin Belg

Predictive factors for cancer-associated thrombosis in a large retrospective single-center study.

Authors : Haltout J, Awada A, Paesmans M, Moreau M, Klastersky J, Machiels G, Ignatiadis M, Kotecki N
Year : 2019
Journal : Support Care Cancer

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

Authors : Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP
Year : 2019
Journal : NPJ Breast Cancer

Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).

Authors : Fontaine C, Renard V, Van den Bulk H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, Vanacker L, de Azambuja E, De Greve J, Awada A, Wildiers H
Year : 2019
Journal : Breast Cancer Res Treat

More publications »

Follow us!

Youtube

Exclusive images of the new Jules Bordet Institute!

Watch the video and discover the major project for the new Jules Bordet Institute. Magnificent images of the construction work on the   80,000 m² dedicated exclusively to cancer are accompanied by explanations on how the project was conceived to combine excellence of patient care with optimal well-being for patients and care staff.

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more